IRIS UniCatt

Autore, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.822
AS - Asia 3.522
EU - Europa 2.539
SA - Sud America 793
AF - Africa 106
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 2
Totale 10.792
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.722
SG - Singapore 1.566
CN - Cina 901
BR - Brasile 633
IT - Italia 541
SE - Svezia 492
VN - Vietnam 363
DE - Germania 333
FR - Francia 318
GB - Regno Unito 160
IE - Irlanda 150
IN - India 142
FI - Finlandia 122
ID - Indonesia 118
UA - Ucraina 102
JP - Giappone 94
RU - Federazione Russa 92
PL - Polonia 69
AR - Argentina 65
BD - Bangladesh 47
CA - Canada 46
HK - Hong Kong 43
TR - Turchia 43
IQ - Iraq 39
MX - Messico 37
KR - Corea 35
EC - Ecuador 30
CI - Costa d'Avorio 26
AT - Austria 24
ZA - Sudafrica 24
NL - Olanda 23
ES - Italia 20
CO - Colombia 19
BE - Belgio 18
CZ - Repubblica Ceca 16
SA - Arabia Saudita 15
MA - Marocco 13
PK - Pakistan 12
PY - Paraguay 12
UZ - Uzbekistan 12
VE - Venezuela 12
EG - Egitto 11
CL - Cile 10
IR - Iran 10
IL - Israele 9
CH - Svizzera 8
PH - Filippine 8
TN - Tunisia 8
AE - Emirati Arabi Uniti 7
DZ - Algeria 7
KE - Kenya 7
NP - Nepal 7
GR - Grecia 6
HU - Ungheria 5
JM - Giamaica 5
KZ - Kazakistan 5
AZ - Azerbaigian 4
JO - Giordania 4
KG - Kirghizistan 4
OM - Oman 4
PT - Portogallo 4
RO - Romania 4
UY - Uruguay 4
XK - ???statistics.table.value.countryCode.XK??? 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
BO - Bolivia 3
CY - Cipro 3
KW - Kuwait 3
LB - Libano 3
LK - Sri Lanka 3
LT - Lituania 3
NO - Norvegia 3
PE - Perù 3
QA - Qatar 3
RS - Serbia 3
SN - Senegal 3
AM - Armenia 2
AO - Angola 2
AU - Australia 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
GA - Gabon 2
GY - Guiana 2
HR - Croazia 2
KH - Cambogia 2
LU - Lussemburgo 2
LV - Lettonia 2
MD - Moldavia 2
MR - Mauritania 2
NI - Nicaragua 2
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
BZ - Belize 1
CR - Costa Rica 1
DK - Danimarca 1
Totale 10.774
Salva come PNG Salva come JPEG
Città #
Singapore 783
Chandler 503
San Jose 386
Ashburn 334
Beijing 218
Rome 148
Dublin 145
Ho Chi Minh City 123
Lauterbourg 106
Jakarta 104
Los Angeles 102
Hefei 98
Hanoi 87
Wilmington 84
Jacksonville 81
Tokyo 81
Frankfurt am Main 79
Dearborn 76
Ann Arbor 75
Council Bluffs 75
Florence 75
San Mateo 75
New York 74
Nanjing 73
Munich 70
Cattolica 69
Hyderabad 69
Lancaster 69
Warsaw 64
Boston 60
Chicago 59
Dallas 59
Milan 56
Princeton 51
Helsinki 48
São Paulo 47
Fairfield 46
Woodbridge 46
The Dalles 44
Marseille 40
Moscow 39
Buffalo 38
Hong Kong 37
Nanchang 37
Seattle 36
Houston 35
Seoul 32
Bremen 27
Abidjan 26
Kent 26
Lappeenranta 25
Lawrence 25
Redwood City 25
Santa Clara 25
Paris 24
Turku 24
Brooklyn 22
Kunming 22
Cambridge 21
Rio de Janeiro 21
Stockholm 21
Orem 20
Izmir 19
Nuremberg 19
Shanghai 19
Tianjin 19
Brussels 18
Atlanta 17
Auburn Hills 17
Redmond 17
St Louis 17
Boardman 16
Da Nang 16
Washington 16
London 15
Naples 15
Pune 15
Shenyang 15
Johannesburg 14
Phoenix 14
Salt Lake City 14
Campinas 13
Guangzhou 13
Hangzhou 13
Baghdad 12
Düsseldorf 12
Elk Grove Village 12
Haiphong 12
Montreal 12
Norwalk 12
Porto Alegre 12
Tampa 12
Tashkent 12
Toronto 12
Vienna 12
Denver 11
Hải Dương 11
Manchester 11
Mountain View 11
Bogotá 10
Totale 6.027
Salva come PNG Salva come JPEG
Nome #
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 331
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 174
Role of microRNAs in Chronic Lymphocytic Leukemia 155
EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS 155
revalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. 149
Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia 147
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 146
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 143
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 141
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 141
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 136
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia 132
Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units 128
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease 122
Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. 121
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics 121
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 120
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 120
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 118
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. 118
What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study 116
Unrelated cord blood transplantation and post-transplant cyclophosphamide 115
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All-Trans Retinoic Acid: A Monocentric Experience 113
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 113
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 111
Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers 111
the concomitance of lymphoma and breast carcinoma in the bone 111
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study 110
COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: what is the role of anti-CD20 antibody? 110
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. 109
Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience 109
Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL 108
Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis 105
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study 105
Chlorambucil PLUS Rituximab As FRONT-LINE THERAPY in Elderly or Unfit Patients Affected by B-CELL Chronic Lymphocytic Leukemia: Results of A Single-Centre Retrospective Analysis 104
Second haploidentical stem cell transplantation for primary graft failure 104
Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax 103
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 102
HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis. 102
Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia 101
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 100
Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience 99
Richter transformation in Chronic Lymphocytic Leukemia 99
Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region 99
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. 99
What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome? 99
Treatment options for elderly/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: A comprehensive review 98
Genetic dynamics in untreated CLL patients with either stable or progressive disease: A longitudinal study 97
Chronic Lymphocitic Leukaemia: Census of Patients Treated in Italian Haematology Units 96
New developments in the management of chronic lymphocytic leukemia: role of ofatumumab 96
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All-Trans Retinoic Acid: A Monocentric Experience 95
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 95
Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients 95
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 95
Unrelated cord blood transplantation and post-transplant cyclophosphamide 95
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 94
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 92
Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study 91
PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay: A highly sensitive method for detection of MYD88 L265P mutation 90
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas 89
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 89
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 89
Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study 88
Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management 88
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia 88
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 88
Days alive outside hospital and readmissions in patients undergoing allogeneic transplants from identical siblings or alternative donors 88
VEGF and IL-6 Correlation in POEMS: A Potential Upcoming Marker of Active Disease and Early Autologous BMT Response 88
Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed 87
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 87
Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia 87
The concomitance of lymphoma and breast carcinoma in the bone 86
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome 85
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: A comprehensive review 83
First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies 83
Relapsed/refractory pure red cell aplasia in chronic lymphocytic leukemia successfully treated with acalabrutinib: a case report and review of the literature 83
Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL. 82
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 81
Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience 81
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia 81
Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review 80
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation 80
Second haploidentical stem cell transplantation for primary graft failure 80
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience 79
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study 79
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience 78
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. 78
Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia 78
New developments in the management of chronic lymphocytic leukemia: role of ofatumumab 76
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia 76
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 75
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia 75
Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units 74
Enhanced expression of mir-181b in b cells of cll improves the anti-tumor cytotoxic t cell response 74
Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience 73
HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia 72
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience 72
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 71
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 71
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 70
Totale 10.216
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.611
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.611
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202188 0 0 0 0 0 0 0 0 0 13 62 13
2021/2022589 51 15 22 24 50 5 7 88 31 33 135 128
2022/20231.442 199 187 106 199 103 193 80 91 165 34 64 21
2023/2024892 39 221 65 77 38 133 65 22 16 34 82 100
2024/20252.000 51 61 135 70 148 60 67 74 226 214 547 347
2025/20264.470 704 190 344 634 725 253 692 271 325 332 0 0
Totale 11.001